Quest Diagnostics (DGX) Tops Q1 EPS by 1c; Guides FY15 In-Line

Quest Diagnostics (NYSE: DGX) reported Q1 EPS of $1.05, $0.01 better than the analyst estimate of $1.04. Revenue for the quarter came in at $1.84 billion versus the consensus estimate of $1.85 billion.

Quest Diagnostics sees FY2015 EPS of $4.70-$4.85, versus the consensus of $4.78. Sees FY2015 revenues to increase 2% to 3% compared to 2014;

"We grew revenues by 5%, adjusted EPS by 13% and adjusted operating income by 14% in the first quarter despite the harsh winter in many parts of the country," said Steve Rusckowski, President and CEO. "We continue to refocus on our core diagnostic information services business and deliver disciplined capital deployment. During the quarter we announced a joint venture with Quintiles to enhance the value of our clinical trials testing business. This month we also completed the debt refinancing and made progress in our commitment to return the majority of free cash flow to shareholders. We're pleased with the continued progress we're making against our five-point strategy."

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.

You May Also Be Interested In

• Lucid reports Q2 output, names new CFO and five other leaders
• Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
• Rivian raises 2026 delivery outlook after Q2 results top guidance